The American National Standard for Excipient GMP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The American National Standard for Excipient GMP
The author reviews significant changes to GMP for excipients in the forthcoming American National Standard, including a risk-based approach to excipient manufacture, why new requirements were proposed, and their potential impact to excipient manufacturers.


Pharmaceutical Technology
Volume 36, Issue 3, pp. s38-s41

New excipient GMP requirements

Excipients come from a broad range of the chemical- and food-ingredient industries. Inorganic excipients usually begin with the mining of minerals. Excipients whose starting material is grown on a farm or forest are often further processed into a derivative through chemical reaction or fermentation. Synthetic excipients can be produced at the manufacturing site from basic chemical starting materials, such as ethylene and acetylene. The one process common to all excipient manufacturing is purification of the material to meet the requirements of a pharmaceutical ingredient. A key challenge of the NSF joint committee, therefore, was to develop excipient GMPs that would be applicable to the diverse operational activities of the excipient industry.

Risk assessment. NSF 363 represents the evolution of the joint IPEC–PQG GMP for Pharmaceutical Excipients (2) into an American National Standard suitable for regulation by FDA. The most significant new requirement in NSF 363 not found in the joint IPEC–PQG guide involves the use of risk management to ensure consistent excipient quality. For the purpose of the article, quality is taken to mean consistent excipient composition and freedom from contamination. Risk assessment is defined in NSF 363 as "a systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards" (1). (For details on conducting and documenting risk assessments as required by the standard, please see the article "Conducting Risk Assessment in Support of ANSI Excipient GMPs" in this issue.) The IPEC–PQG excipient GMP guide, as well as other IPEC guides, provide additional resources for risk assessment. The purpose of the many risk assessments stipulated in NSF 363 is to identify risks to excipient quality to assure control measures are commensurate with those risks (1). Several sections and clauses of the new standard are explained below. Note that the term "Section" as used in this article refers to requirements that also contain enumerated subordinate requirements referred to herein as "Clauses."

The first clause in NSF 363 to refer to risk is 4.2.1 (Quality Management System/ Documentation Requirements/General) where the appropriate use of quality risk-management principles, defined as a systematic process for the assessment, control, communication, and review of risks to the quality of the excipient across its life cycle, are to be used to evaluate changes to the quality management system. Such changes include activities, operations, and processes that pose a risk to excipient quality. Also in this clause is the requirement to document a risk assessment that justifies those other clauses of the standard that do not apply to excipient manufacture and are thus not implemented.

Section 4.3 on Quality Management System/Change Control requires the implementation of risk assessment as a tool to determine the impact of change involving the manufacture of the excipient. Here, IPEC–Americas has provided a guide as a basis for conducting the risk assessment. Any change that may impact the consistent composition or performance of the excipient should be considered potentially significant and the pharmaceutical customer should be notified as suggested in the IPEC guide for significant change reporting (4).

Section 6 on Resource Management requires several risk assessments to identify the potential for contamination of the excipient. For example:

  • Clause 6.2.3 (Human Resources/Hygienic Practices) describes risk assessment to identify the potential for contamination of the excipient by personnel and/or their activities. Where a risk to the excipient exists, the standard provides five measures that may be taken to minimize said risk. The proposed control measures will be familiar to manufacturers who have implemented excipient GMPs as noted in the IPEC–PQG guide (2).
  • Clause 6.3.1 (Infrastructure/Buildings and Facilities) requires risk assessment to evaluate the threat to excipient contamination posed by the buildings and facilities. This assessment is to consider the intended use of the excipient (i.e., oral, parenteral, topical applications, etc.). The five aspects presented for consideration are discussed in the IPEC–PQG guide (2). The provision to perform the risk assessment relative to the marketed intended use of the excipient links how the excipient is marketed to the tolerance for risk of contamination from the manufacturing facility.
  • Clause 6.3.3 (Utilities) stipulates evaluation of contamination risk from utilities but does not require linkage to the intended use of the excipient.
  • Section 6.4 on Work Environment requires the assessment of contamination risk from exposure to the work environment. This risk assessment is linked to customer requirements and marketed use. The standard notes five control measures that are to be considered when conducting this assessment for risk. The clauses under 6.4 require documentation of conformance to the control measures implemented to address the risk to excipient quality noted in the assessment. However, Clause 6.4.4 (Pest Control) provides for a risk assessment to identify the elements needed in a pest control program.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here